Filtered By Specialty: Service Category: Key Service: Region: Country:

Company Profiles2,311-2,320 of 4,244 Companies

Want to add your company?

GET FULL ACCESS!

USER GUIDE DATABASE // PRICING // FAQ
Any question? Contact us!

Laboratoire L'Ideal Parisien

  • Contract manufacturing, filling and packaging
  • Animal Medicines
  • Europe

More »

Zamann Pharma Support GmbH

  • Consulting - strategy and development
  • Human Medicines
  • Europe

More »

Orus Research

  • Pre-clinical development and testing, pre-clinical CRO
  • Animal Medicines
  • Europe

More »

FMD K&L

  • eData - IT - software
  • Human Medicines
  • Europe

More »

Liposoma

  • Formulation development and drug delivery
  • Biopharmaceuticals
  • Europe

More »

León Research, s.l.

Logo León Research, s.l.
  • Pre-clinical development and testing, pre-clinical CRO
  • Human Medicines
  • Europe

We, León Research, S.L are a Spanish CRO, providing outsourcing services for the Pharma Industry, Biotech companies, and Medical Devices Manufacturers, with a wide experience on clinical research, mainly developing Phase I to IV clinical trials, medical devices and observational studies. We assume that on scientist researching the two key factors are the intelligence and creativity, and we apply this principles in all our work. Our solutions include all the process from design and consultancy for clinical trial development to the statistic analysis, covering the whole process to introduce new medical devices and pharmacy products on the market. Our quality policy is based on compliance with the ICH/GCP, the use of the best procedures in each study and looking for the satisfaction of our clients. Intelligence, Creativity and Honesty are the main principles in which we sustain our activity. Orus Research is our division specialized in preclinical. We are a CRO specialized in ophthalmology headquartered in Spain. Designed specifically for preclinical and clinical research in ophthalmology offering a global service from early proof of concept evaluation, modeling effective and preclinical research and development of clinical trials. More »

PharmaVize

Logo PharmaVize
  • Contract manufacturing, filling and packaging
  • Human Medicines
  • Europe

You have a promising (New) Chemical Entity and you are preparing for Preclinical or Early Phase Clinical Studies? You are looking for contractors who can characterise, formulate, GMP produce, label and release your clinical trial material? Well, here you have found a single, reliable source that can meet your clinical supply material needs. Our business is to develop and manage your Early Clinical Supply Materials from design to delivery. We offer you an integrated and tailored service level. More »

Exquiron

Logo Exquiron
  • Pre-clinical development and testing, pre-clinical CRO
  • Human Medicines
  • Europe

Exquiron is dedicated to contract research in early stage drug discovery. Our services span from assay development and adaptation for hit finding and profiling purposes to compound selection, high throughput screening, selectivity testing and hit characterization, and SAR expansion. Our scientists will work with you to identify the most suitable approach to reach your program milestones as rapidly, efficiently and economically as possible. Our team brings proven expertise to all areas of the hit identification process, including broad target class coverage, assay systems and technologies, assembly of compound screening decks, high throughput screening, data processing, mining and interpretation, quality control, project management, and reporting. Exquiron is now part of the Aptuit group of companies. More »

SCIENTEX

Logo SCIENTEX
  • Consulting - strategy and development
  • Human Medicines
  • Europe, North America, South America, Asia, Australia & New Zealand, Worldwide

Mandated by its clients, Scientex is acting globaly and pragmatically on all aspects of corporate development and corporate finance, and supports them on strategic Intelligence & business communication with specific tools : http://www.scientex.eu/5.html   The objective of SCIENTEX is to allow its clients to enjoy its experience from science to stock exchange, in order to act in the name and on behalf of them, the most effectively possible at corporate level :   http://www.scientex.eu/resources/What+is+the+real+full+cost+of+an+employee.pdf   and to keep on saving time for its clients , being immediately operational. Scientex’s associates are structured to be able to work effectively 60% more than the average working time in Europe : see details in our competitiveness.  Last but not least, working with Scientex will allow you to reduce your labor costs thank to our low cost fees :  http://www.scientex.eu/4.html   Tim Muller founded SCIENTEX : his background : 10 years as a private equity investor & 10 years as a corporate developer, both focused on healthcare industry : Tim started his R&D career as a project engineer on radio-pharmaceuticals at AREVA / CEA in 1993, moved as a pre-clinical pharmaco-chemist for SERVIER laboratories on diabete mellitus & CNS up to pharmaceutical proof of concept & industrial scalability. In 1999, Tim switched to the private equity industry (CDC enterprises & Sofimac Partners) investing in 17 healthcare private companies selected from its 600 life sciences deal flow proactively sourced : 6 companies were acquired by industrials & 4 IPOs, 2 are still private, 5 bankruptcies; generating a double digit IRR . To date, Tim served a "hands on" board member on 23 healthcare companies in Europe. Then, Tim created SCIENTEX in 2006 in order to act as a day to day transition manager in business & corporate development, and M&A (buy & sell side) for small and mid healthcare companies, while he was advising in parallel wealthy individuals on VIX trading & working with private equity funds. Complementary, Tim & Berenice Muller created BIOTECHNEWS, a corporate and financial communication service, targeting up to 500K life sciences investors & industrials including 20% of VP and C-level and board members and 30 000 dealsmakers inside pharma industry.   After +26 corporate development missions in 6 years generating +1Meuros of net profit for Scientex, Tim joined CROSSJECT in 2012 during its restart in order to drive the new business & corporate development.    Then, after the succesful completion of a 472M$ licensing deal; Tim, in its position of member of the executive board, led the $6M refinancing closed in june 2013, managed M&A opportunities & engaged the IPO process, successfully oversubscribed 4,4 x in february 2014 (Photo1 & Photo2). Globally, Tim has been involved in 100 corporate and business transactions to date, including 5 IPOs and 9 M&A   Berenice Muller, now managing director of SCIENTEX, PharmD (2001) & Master degree in Medtech, is developing Scientex offer’s in business development towards European SME in order to cover deeply the 5EU market, while Tim focuses on international operations for all Scientex's clients. Berenice is also updating SCIENTEX's contact database (+30 000 in pharma/biotech deal makers) and SCIENTEX's intelligence database (+21 000 market studies) :  see http://www.scientex.eu/5.html Tim Muller French Landline: +33 240 450 821 (main) French Mobile: +33 645 523 540 tm@scientex.eu (main) Skype id: timotheemuller French Fax: +33 897 502 069 fr.linkedin.com/in/timotheemuller More »

Aptys Pharmaceuticals

  • Formulation development and drug delivery
  • Human Medicines
  • Europe

Since 2002, as a contract research and development organization, we offer to our customers: • Quality control and ICH stability, analytical development and validations • Custom-made formulation and generic development • Production assistance More »

Companies by service category

Companies by regionCompanies by specialty

Outsourcing?

Looking for special service?
Don't spend time on search!

Place Request Anonymously »

Get applications from providers For Free